ArticleCureus2025
Regional Disparities in Multiple Sclerosis Care in Poland: Epidemiology, Workforce Challenges, and Continuity of Care.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system with a substantial socioeconomic burden. Despite universal healthcare coverage, disparities in access to specialized care and disease-modifying treatment persist in Poland. Understanding these disparities, particularly their regional dimension, is essential for optimizing workforce planning and improving continuity of care. Methods I conducted a retrospective, nationwide analysis of MS epidemiology, neurology workforce availability, treatment infrastructure, and patient care pathways in Poland using official health statistics from 2009 to 2023. Data included prevalence, incidence, number, and age structure of neurologists, distribution of first- and second-line treatment centers, patient migration rates, and waiting times between the first and second visit. Descriptive statistics and correlation analyses were performed at the regional level. Results Between 2019 and 2023, MS prevalence increased by 11.6% (from 61,693 to 68,850 cases), while incidence remained stable (+2.3%). The number of neurologists grew by only 3.4%, with over one-third at retirement age in several regions. Patient load per neurologist varied twofold across regions (11.6 in Mazowieckie vs. 21.0 in Opolskie), and higher workloads were associated with longer waiting times (r = 0.42) and higher patient migration rates (r = 0.39). The median waiting time between the first and second visit was 30 days, but exceeded 90 days for one in five patients. Regions with fewer second-line treatment centers and aging workforces showed the greatest continuity-of-care challenges. Conclusions Significant regional disparities in MS care exist in Poland, driven by uneven workforce distribution, an aging neurology workforce, and unequal access to specialized centers. Targeted interventions should prioritize high-burden, underserved regions, expand second-line treatment capacity, and address workforce aging to ensure equitable and timely care for MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.